Hi,
I am trying to send a collection of Collection<? extends BaseClass>
The collection it is actually populated with DerivedClass1 and DerivedClass2
objects.
It this possible?
I found the following snippet for spring configuration in the server.
<bean id="aegisContext" class="org.apache.cxf.aegis.AegisContext"
scope="prototype">
<property name="writeXsiTypes" value="true" />
<property name="rootClassNames">
<list>
<value>com.package.DerivedClass1</value>
<value>com.package.DerivedClass2</value>
</list>
</property>
</bean>
<simple:server id="service" address="/Service"
serviceClass="com.package.Service" serviceBean="#service">
<simple:dataBinding>
<bean
class="org.apache.cxf.aegis.databinding.AegisDatabinding">
<property name="aegisContext" ref="aegisContext"
/>
</bean>
</simple:dataBinding>
...
</simple:server>
In the client I get lots of:
WARN: org.apache.cxf.aegis.type.TypeUtil.getReadType(TypeUtil.java:88):
xsi:type absent, and no type available for member of DerivedClass*
Should I enable the AegisContext also in the client?
readXsiTypes looks like that defaults to true.
Thanks
--
__________________________________
Vassilis Virvilis Ph.D.
Head of IT
Biovista Inc.
Stay tuned
www: http://www.biovista.com
LinkedIn: https://www.linkedin.com/company/biovista
Twitter: https://twitter.com/BiovistaInc/
Vizit https://twitter.com/BiovistaVizit/
Facebook: https://www.facebook.com/biovistainc
Vizit (research): https://www.facebook.com/BiovistaVizit
YouTube: https://www.youtube.com/user/BiovistaInc
--
US Offices
2421 Ivy Road
Charlottesville, VA 22903
USA
T: +1.434.971.1141
F: +1.434.971.1144
European Offices
34 Rodopoleos Street
Ellinikon, Athens 16777
GREECE
T: +30.210.9629848
F: +30.210.9647606
Biovista is a privately held biotechnology company that finds novel uses for
existing drugs, and profiles their side effects using their mechanism of
action. Biovista develops its own pipeline of drugs in CNS, oncology,
auto-immune and rare diseases. Biovista is collaborating with biopharmaceutical
companies on indication expansion and de-risking of their portfolios and with
the FDA on adverse event prediction.
